# Ryan J. Sullivan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ryan-j-sullivan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 46,550 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 91 |
| i10-index | 338 |
| Last Known Institution | Harvard University |
| OpenAlex ID | https://openalex.org/A5008479799 |
| ORCID iD | https://orcid.org/0000-0001-5344-6645 |
| Works | 1,126 |

## Researcher papers

Showing 12 of 13.

- [Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq](https://scholariq.org/papers/dissecting-the-multicellular-ecosystem-of-metastatic-melanoma-by-single-cell-rna/)
- [Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma](https://scholariq.org/papers/defining-t-cell-states-associated-with-response-to-checkpoint-immunotherapy-in/)
- [A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade](https://scholariq.org/papers/a-cancer-cell-program-promotes-t-cell-exclusion-and-resistance-to-checkpoint/)
- [<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis](https://scholariq.org/papers/i-egfr-i-mutations-and-i-alk-i-rearrangements-are-associated-with-low-response/)
- [Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma](https://scholariq.org/papers/overall-survival-benefit-with-tebentafusp-in-metastatic-uveal-melanoma/)
- [Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab](https://scholariq.org/papers/anti-pd-1-therapy-in-patients-with-advanced-melanoma-and-preexisting-autoimmune/)
- [Transforming Fusions of <i>FGFR</i> and <i>TACC</i> Genes in Human Glioblastoma](https://scholariq.org/papers/transforming-fusions-of-i-fgfr-i-and-i-tacc-i-genes-in-human-glioblastoma/)
- [Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer](https://scholariq.org/papers/microenvironment-drives-cell-state-plasticity-and-drug-response-in-pancreatic/)
- [Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy](https://scholariq.org/papers/melanoma-specific-mhc-ii-expression-represents-a-tumour-autonomous-phenotype-and/)
- [Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade](https://scholariq.org/papers/targeted-next-generation-sequencing-identifies-markers-of-response-to-pd-1/)
- [Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma](https://scholariq.org/papers/defining-t-cell-states-associated-with-response-to-checkpoint-immunotherapy-in-2/)
- [The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors](https://scholariq.org/papers/the-incidence-causes-and-risk-factors-of-acute-kidney-injury-in-patients/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)

## Researcher university

- [Harvard University](https://scholariq.org/institutions/harvard-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.